You are here

Our science / Clinical Trials / Find a Trial / NCT00174291

Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy

Back to Search Print Save as PDF Bookmark Trial

NCT00174291

Last updated on February 21, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Paris, , 75019 France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Endocrine System Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
4-14 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- This study will be proposed to all patients previously included in study CTN
97-8129-016

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Discontinuation of corticosteroid therapy for more than a year during study CTN
97-8129-016

- Patients withdrawing from the study prematurely

NCT00174291
Pfizer
Terminated
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Endocrine System Diseases
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215
All Genders
11+
Years
Multiple Sites
Diabetes Mellitus, Type 2 Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
NCT01301456
Females
18+
Years
Multiple Sites
Endocrine System Diseases
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
NCT00174291
All Genders
4+
Years
Paris,
Endocrine System Diseases
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
NCT00174187
All Genders
11+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now